Austin D. Kim
Net Worth

Last updated:

What is Austin D. Kim net worth?

The estimated net worth of Mr. Austin D. Kim is at least $5,644,939 as of 8 Jan 2024. He owns shares worth $1,171,118 as insider, has earned $713,261 from insider trading and has received compensation worth at least $3,760,560 in ACADIA Pharmaceuticals Inc..

What is the salary of Austin D. Kim?

Mr. Austin D. Kim salary is $626,760 per year as Executive Vice President, Gen. Counsel & Sec. in ACADIA Pharmaceuticals Inc..

How old is Austin D. Kim?

Mr. Austin D. Kim is 61 years old, born in 1964.

What stocks does Austin D. Kim currently own?

As insider, Mr. Austin D. Kim owns shares in one company:

Company Title Shares Price per share Total value
ACADIA Pharmaceuticals Inc. (ACAD) Executive Vice President, Gen. Counsel & Sec. 46,901 $24.97 $1,171,118

What does ACADIA Pharmaceuticals Inc. do?

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

ACAD logo
ACAD
ACADIA Pharmaceuticals Inc.
$24.97

Austin D. Kim insider trading

ACADIA Pharmaceuticals Inc.

Mr. Austin D. Kim has made 15 insider trades between 2019-2024, according to the Form 4 filled with the SEC. Most recently he sold 590 units of ACAD stock worth $17,676 on 8 Jan 2024.

The largest trade he's ever made was exercising 36,174 units of ACAD stock on 5 Oct 2023. As of 8 Jan 2024 he still owns at least 46,901 units of ACAD stock.

Transaction Date Security Shares Price per share Total value Source
Sale
Common Stock 590 $29.96 $17,676
Option
Restricted Stock Units 1,634 N/A N/A
Option
Common Stock 1,634 N/A N/A
Sale
Common Stock 16,369 $21.96 $359,463
Option
Restricted Stock Units 36,174 N/A N/A
Option
Common Stock 36,174 N/A N/A
Sale
Common Stock 917 $21.18 $19,422
Option
Restricted Stock Units 3,005 N/A N/A
Option
Common Stock 3,005 N/A N/A
Sale
Common Stock 1,456 $18.16 $26,441
Option
Common Stock 4,773 N/A N/A
Option
Restricted Stock Units 4,773 N/A N/A
Sale
Common Stock 803 $18.78 $15,080
Option
Restricted Stock Units 2,214 N/A N/A
Option
Common Stock 2,214 N/A N/A
Sale
Common Stock 589 $17.13 $10,090
Option
Restricted Stock Units 1,633 N/A N/A
Option
Common Stock 1,633 N/A N/A
Option
Restricted Stock Units 3,005 N/A N/A
Sale
Common Stock 894 $18.18 $16,255
Option
Common Stock 3,005 N/A N/A
Option
Common Stock 2,213 N/A N/A
Option
Restricted Stock Units 2,213 N/A N/A
Sale
Common Stock 782 $23.8 $18,612
Option
Common Stock 1,633 N/A N/A
Option
Restricted Stock Units 1,633 N/A N/A
Sale
Common Stock 574 $23.05 $13,231
Sale
Common Stock 1,054 $20.33 $21,428
Option
Restricted Stock Units 3,005 N/A N/A
Option
Common Stock 3,005 N/A N/A
Sale
Common Stock 2,107 $50.61 $106,635
Option
Restricted Stock Units 1,633 N/A N/A
Sale
Common Stock 678 $53.34 $36,165
Option
Common Stock 1,633 N/A N/A
Option
Stock Option (Right to Buy) 8,750 N/A N/A
Option
Common Stock 8,750 N/A N/A
Sale
Common Stock 8,750 N/A N/A
Sale
Common Stock 1,072 $49.22 $52,764
Option
Restricted Stock Units 3,004 N/A N/A
Option
Common Stock 3,004 N/A N/A
Option
Common Stock 17,500 N/A N/A
Option
Stock Option (Right to Buy) 17,500 N/A N/A
Sale
Common Stock 17,500 N/A N/A

ACADIA Pharmaceuticals key executives

ACADIA Pharmaceuticals Inc. executives and other stock owners filed with the SEC: